The clinical efficacy of tocilizumab in rheumatoid arthritis

Drugs of Today

Volumn 45, Issue 3, 2009, Pages 189-197

  Mircic, Maja ^a   Kavanaugh, Arthur ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATLIZUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; INTERLEUKIN 6; METHOTREXATE;

CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; HUMAN; MONOTHERAPY; REVIEW; RHEUMATOID ARTHRITIS; SINGLE DRUG DOSE; TREATMENT OUTCOME;

EID: 67749084409     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2009.45.3.1343794     Document Type: Review

References (16)

1. Ackermann, C., Kavanaugh, A. Tumor necrosis factor as a therapeutic target of rheumatologic disease. Expert Opin Ther Targets 2007,11(11): 1369-1384 (Pubitemid 350200476)
2. Lipsky, P.E. Interleukin-6 and rheumatic diseases. Arthritis Res Ther 2006, 8(Suppl. 2): S4.
3. Yoshizaki, K., Nishimoto, N., Mihara, M., Kishimoto, T. Therapy of rheumatoid arthritis by blocking IL-6 signal transduction with humanized anti-IL-6 receptor antibody. Springer Semin Immunopathol 1998, 20(1-2): 247-259 (Pubitemid 28502460)
4. Nishimoto, N., Yoshizaki, K., Maeda, K. et al. Toxicity, pharmacokinetics and dose finding study of repetitive treatment with the humanized anti-interleukin-6 receptor antibody MRA in rheumatoid arthritis. J Rheumatol 2003, 30(7): 1426-1435 (Pubitemid 36835435)
5. Choy, E.H.S., Isenberg, D.A., Garrood, T. et al. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis. A randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum 2002, 46(12): 3143-3150
6. Nishimoto, N., Yoshizaki, K., Miyasaka, N. et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multi-center, double-blind, placebo-controlled trial. Arthritis Rheum 2004, 50(6): 1761-1769 (Pubitemid 38725087)
7. Nishimoto, N., Miyasaka, N., Yamamoto, K., Kawai, S., Takeuchi, T., Azuma, J., Kishimoto, T. Long-term safety and efficacy of tocilizumab (an anti-IL-6 receptor monoclonal antibody) in monotherapy in patients with rheumatoid arthritis. Ann Rheum Dis 2007, 66(Suppl. 2): 122.
8. Maini, R.N., Taylor, P.C., Szechinski, J. et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 2006, 54(9): 2817-2829 (Pubitemid 44497760)
9. Smolen, J., Beaulieu, A., Rubbert-Roth, A. et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): A double-blind, placebo-controlled, randomised trial. Lancet 2008, 371(9617): 987-997
10. Genovese, M., McKay, J., Nasonov, E. et al. IL-6 receptor inhibition with Tocilizumab reduces disease activity in patients with rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs. Arthritis Rheum 2008, 58(10): 2968-2980
11. Nishimoto, N., Hashimoto, J., Miyasaka, N. et al. Study of active controlled monotherapy used for rheumatoid arthritis, and IL-6 inhibitor (SAMURAI): Evidence of clinical and radiographic benefit from an x-ray reader-blinded randomized controlled trial of tocilizumab. Ann Rheum Dis 2007, 66(9): 1162-1167 (Pubitemid 47309731)
12. Ohsugi, Y., Kishimoto, T. The recombinant humanized anti-IL-6 receptor antibody tocilizumab, an innovative drug for the treatment of rheumatoid arthritis. Expert Opin Biol Ther 2008, 8(5): 669-681
13. Kremer, J., Fleischmann, R., Halland, A.-M. et al. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with an inadequate response to methotrexate: the LITHE study. Arthritis Rheum 2008, 58(12): 4031.
14. Emery, P., Keystone, E., Tony, H.P. et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial Ann Rheum Dis 2008, 67(11): 1516-1523
15. Nishimoto, N., Miyasaka, N., Yamamoto, K., Kawai, S., Takeuchi, T., Azuma, J., Kishimoto, T. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): Significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol. 2009, 19(1): 12-19
16. Nishimoto, N., Miyasaka, N., Yamamoto, K., Kawai, S., Takeuchi, T., Azuma, J. Long-term safety and efficacy of tocilizumab, an anti-interleukin-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): Evidence of safety and efficacy in a 5-year extension study. Ann Rheum Dis 2008, Nov 19 (Epub ahead of print).